Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-05-09

Clinical Trial Update: Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and immunogenicity of three potencies of the V181 dengue vaccine in adults; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • V181 Dengue Vaccine

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Dengue Disease, Dengue Virus | Phase 2 | Status: COMPLETED | Results posted: 2025-05-09